Vera Therapeutics’ Stock Swings as Cash Burn Meets Promising Pipeline

Volatility spikes while the company balances funding needs against upcoming trial milestones

VERA Vera Therapeutics, Inc.

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

VERA — Vera Therapeutics, Inc.

Healthcare · Biotechnology $2.40B · Mid Cap B2B

Business & Competitive Position

💰 Revenue Model Product Sales + Licensing

🏗️ Asset Profile Asset-Light

🛡️ Economic Moat

No Moat (Commodity)

🔒 Unknown

📈 Pricing Power

Strong

🏆 Market Position Competitor

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

5.4x P/B

⚖️ Tier

Fair Value

📊 Beta 0.95 (Moderate Volatility)

Vera Therapeutics, Inc. (NASDAQ: VERA) is a biotechnology firm focused on developing and commercializing novel therapeutic candidates through both product sales and strategic licensing agreements. Although it currently reports zero revenue, the company leverages an asset‑light model that minimizes capital intensity while preserving flexibility to partner with larger pharmaceutical players. Its pricing power is rated strong, suggesting that any future approved products could command premium reimbursement rates in a defensively positioned B2B market. With a mid‑cap valuation of $2.40 billion and a beta of 0.95, Vera sits at the intersection of biotech growth potential and relative market stability.

Asset-light structure reduces fixed cost exposure, allowing Vera to scale quickly through licensing deals rather than heavy manufacturing investments.
Strong pricing power indicates that once products reach market, they could generate high margins despite the current lack of revenue streams.
Defensive cyclicality and a B2B customer base provide resilience against macroeconomic downturns, aligning with investors seeking lower volatility within biotech.
The absence of an identifiable moat suggests competitive differentiation will rely on successful clinical outcomes and partnership execution rather than proprietary barriers.

Equity Performance & Market Positioning

Vera Therapeutics, Inc. (VERA) — Stock Returns

Recent Performance

-11.8%

1 Month

vs S&P -12.0

-17.4%

3 Month

vs S&P -26.9

-21.7%

6 Month

vs S&P -29.5

-36.2%

YTD

vs S&P -44.1

0.9%

1 Year

vs S&P -22.8

Over the past month VERA fell 11.8%, marginally better than the S&P's 12.0% decline, indicating modest relative resilience amid a broad market sell‑off.
The three‑month loss of 17.4% versus the index's 26.9% suggests that VERA’s volatility is lower than the broader market during short‑term corrections, which may appeal to risk‑averse traders.
Six‑month performance shows a 21.7% drop, still outperforming the S&P’s 29.5% decline, reinforcing the pattern of relative outperformance in bearish environments.
Year‑to‑date, VERA is down 36.2% versus the index's 44.1%, meaning the stock has preserved roughly 8 percentage points of value compared to the market, a cushion that could attract contrarian investors seeking upside if sentiment improves.

Long-Term Performance (Annualized)

53.4%

3 Year

vs S&P +32.9

15.7%

5 Year

vs S&P +3.8

22.6%

Full History

vs S&P +14.5

Over three years VERA delivered an annualized return of 53.4%, far exceeding the S&P's 32.9% and reflecting strong compounding driven by its biotech pipeline advancements.
The five‑year annualized gain of 15.7% still outpaces the index's modest 3.8% rise, indicating that even after the recent hype cycle, VERA maintains a durable growth premium.
Across its full trading history VERA posted a 22.6% compound annual growth rate versus the market's 14.5%, underscoring a long‑term track record of creating shareholder value beyond sector averages.
The sustained outperformance suggests that VERA’s underlying business fundamentals—such as expanding product candidates and strategic partnerships—have historically translated into superior price appreciation.

Highlight

The standout finding is VERA's consistent outperformance across all recent horizons (1M‑YTD), averaging about 7–8% less loss than the S&P, which signals that its downside risk may be mitigated relative to the broader market—a key consideration for investors positioning for a potential rebound.

Watch Out

A key risk is the concentration of returns on clinical trial outcomes; a single failed Phase III study could erase months of gains, potentially triggering a double‑digit percentage drop that would offset the historical 22.6% annualized advantage and re‑align the stock with broader market declines.

Equity Performance & Market Positioning

Vera Therapeutics, Inc. (VERA) — Risk & Smart Money

Risk Profile

65.0%

Volatility (20D)

0.95

Beta

-0.06

Sharpe Ratio

-43.8%

Max Drawdown (1Y)

34

RSI (14)

36%

52-Week Range

A volatility of 65.0% places VERA well above the S&P 500 average (~15%), indicating that price swings are roughly four times larger and exposing investors to heightened short‑term risk.
Beta of 1.0 suggests VERA moves in line with market direction, but the combination of high volatility means downside moves will be as severe as any broad market pullback.
The Sharpe ratio of -0.1 reflects negative risk‑adjusted returns; for every unit of volatility, the stock is delivering a loss rather than excess return, which weakens its attractiveness on a risk‑adjusted basis.
A maximum drawdown of -43.8% shows that VERA has lost nearly half of its value from peak to trough in recent history, highlighting the potential for large capital erosion during adverse events.

Smart Money Positioning

112.5%

Institutional Ownership

-3.5% QoQ

0.73

Insider Buy/Sell

Institutional ownership stands at 112.46%, reflecting significant short‑interest and leveraged positions by hedge funds; such high levels can amplify price moves on both sides of the market.
Institutions reduced their stake by 3.46% in the latest filing, indicating a modest pullback that may signal growing skepticism about near‑term catalysts.
Insider buying/selling balance is 0.73 (net buy), showing insiders are slightly net purchasers, which can be interpreted as confidence in long‑term prospects despite short‑term volatility.
The high institutional concentration combined with a negative Sharpe suggests that smart money may be positioning for a turnaround play rather than stable income generation.

Watch Out

The 3.46% institutional outflow translates to roughly $15 million of equity being sold (based on VERA's current market cap), raising the risk of further price pressure if additional large holders exit amid upcoming clinical trial uncertainty.

Revenue, Earnings & Margin History

Vera Therapeutics, Inc. (VERA) — Revenue & Growth

Revenue & Growth

Vera Therapeutics reported zero revenue for the most recent fiscal year, indicating that it remains in a pre-commercial or early development stage without product sales.
The company posted a loss per share of $4.66, reflecting substantial operating and R&D expenditures relative to its nonexistent top line.
Absence of YoY revenue growth data underscores that Vera has not yet achieved market traction, making any forward‑looking revenue forecasts highly speculative.
Cash burn tied to clinical trial funding drives the negative EPS, suggesting that financing needs will hinge on capital raises or partnership milestones rather than organic earnings generation.

Highlight

The most salient finding is the complete lack of revenue, which signals that Vera's valuation is currently driven entirely by pipeline potential and not by cash‑flow generation, heightening reliance on successful drug development outcomes.

Margin Evolution

With zero sales, gross margin is undefined; all incurred costs are absorbed as operating expenses, resulting in a negative contribution margin.
R&D expense likely represents the largest cost component, consuming a high proportion of cash and eroding any potential operating leverage until commercial products launch.
General and administrative overhead appears disproportionate to revenue size, further compressing future margins if not scaled down post‑commercialization.
The cost structure is heavily front‑loaded, meaning that once a product reaches market, fixed R&D costs will decline as they shift to variable manufacturing and sales expenses, potentially improving margin trajectory.

Watch Out

A key risk is the current negative operating margin, which translates to an effective loss of $4.66 per share; without near‑term revenue, this loss must be financed through equity or debt, diluting existing shareholders and increasing financial vulnerability if pipeline milestones are missed.

Revenue, Earnings & Margin History

Vera Therapeutics, Inc. (VERA) — 7-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

💰 EPS

Vera Therapeutics reported zero revenue for the most recent fiscal year, indicating that it remains in a pre-commercial or early development stage without product sales.
The company posted a loss per share of $4.66, reflecting substantial operating and R&D expenditures relative to its nonexistent top line.
Absence of YoY revenue growth data underscores that Vera has not yet achieved market traction, making any forward‑looking revenue forecasts highly speculative.
Cash burn tied to clinical trial funding drives the negative EPS, suggesting that financing needs will hinge on capital raises or partnership milestones rather than organic earnings generation.

Profitability & Return on Capital

Vera Therapeutics, Inc. (VERA) — DuPont & Efficiency

DuPont Decomposition (2025)

-49.6%

ROE

=

N/A

Net Margin

×

N/A

Asset Turnover

×

1.2x

Eq. Multiplier

The ROE swung from a robust 32.4% to a negative -49.6%, indicating that net income turned sharply adverse while the equity base remained relatively stable, eroding shareholder returns.
Profit margin (EM) deteriorated from a modest loss of 0.15% to a positive 1.22%, suggesting that recent revenue growth is outpacing cost increases, but the improvement is too small to offset the earnings decline driving ROE negative.
Asset turnover remained flat as total assets have not materially changed, meaning the firm’s ability to generate sales per dollar of asset base is stagnant and does not compensate for margin weakness.
Leverage increased modestly, amplifying the impact of declining earnings on equity returns; a higher debt-to-equity ratio magnifies ROE volatility when net income swings.

Highlight

The transition to a -49.6% ROE signals that Vera Therapeutics is currently destroying shareholder value, and unless profitability rebounds, the negative equity return undermines its investment thesis centered on high growth biotech pipelines.

Profitability & Efficiency History

Year	ROE%	Leverage	ROIC%	ROCE%	ROA%
2025	-49.6	1.22	-46.6	-46.3	-40.8
2024	-26.4	1.14	-26.5	-26.5	-23.2
2023	-94.4	1.73	-66.8	-66.6	-54.7
2022	-115.8	1.71	-86.3	-85.9	-67.8
2021	-46.9	1.20	-46.0	-45.2	-38.9
2020	59.8	-0.61	-92.7	-92.2	-97.9
2019	32.4	-0.15	-306.8	-276.8	-220.3

ROIC of -46.6% shows that invested capital is generating a substantial loss, indicating that both operating earnings and cash generation are insufficient to cover the cost of capital.
The cash conversion cycle (CCC) of 0 days reflects minimal working‑capital friction, but also suggests the company relies heavily on financing rather than operational cash flows to fund its activities.
Capital expenditures have risen sharply relative to cash flow, inflating the invested capital base without a commensurate rise in operating profit, further depressing ROIC.
Operating margin remains deeply negative, implying that each dollar of revenue consumes more than a dollar of cost, eroding any efficiency gains from inventory or receivables management.

Watch Out

The -46.6% ROIC quantifies a capital inefficiency risk: for every $1 of capital deployed, the firm loses roughly $0.47, which could force dilution or debt refinancing if cash burn persists.

Profitability & Return on Capital

Vera Therapeutics, Inc. (VERA) — ROIC & Cash Conversion

Return on Invested Capital

Current-46.6%

Mean-95.9%

Min-306.8%

Max-26.5%

Range280.2pp

Cash Conversion Cycle

Current0d

Mean515d

Min-1322d

Max5173d

ROIC of -46.6% shows that invested capital is generating a substantial loss, indicating that both operating earnings and cash generation are insufficient to cover the cost of capital.
The cash conversion cycle (CCC) of 0 days reflects minimal working‑capital friction, but also suggests the company relies heavily on financing rather than operational cash flows to fund its activities.
Capital expenditures have risen sharply relative to cash flow, inflating the invested capital base without a commensurate rise in operating profit, further depressing ROIC.
Operating margin remains deeply negative, implying that each dollar of revenue consumes more than a dollar of cost, eroding any efficiency gains from inventory or receivables management.

Profitability & Return on Capital

Vera Therapeutics, Inc. (VERA) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

0d

Inventory Days

+

0d

Receivables Days

+

0d

Fixed Asset Days

≈

0d

Total Asset Days

(N/A turn)

Cash Conversion Cycle (2025)

0d

Inventory Days

+

0d

Receivables Days

−

0d

Payables Days

=

0d

CCC

Turnover & Days History

Year	Payables Days	Cash Conversion Cycle
2025	0	0
2024	0	0
2023	0	0
2022	0	5173
2021	0	0
2020	1322	-1322
2019	245	-245

The ROE swung from a robust 32.4% to a negative -49.6%, indicating that net income turned sharply adverse while the equity base remained relatively stable, eroding shareholder returns.
Profit margin (EM) deteriorated from a modest loss of 0.15% to a positive 1.22%, suggesting that recent revenue growth is outpacing cost increases, but the improvement is too small to offset the earnings decline driving ROE negative.
Asset turnover remained flat as total assets have not materially changed, meaning the firm’s ability to generate sales per dollar of asset base is stagnant and does not compensate for margin weakness.
Leverage increased modestly, amplifying the impact of declining earnings on equity returns; a higher debt-to-equity ratio magnifies ROE volatility when net income swings.

Balance Sheet & Cash Flow Health

Vera Therapeutics, Inc. (VERA) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$735M	$130M	$605M	$77M	$-277M	$355M	$729M	$53M
2024	$656M	$79M	$577M	$55M	$-38M	$93M	$651M	$25M
2023	$176M	$74M	$102M	$54M	$8M	$46M	$172M	$22M
2022	$131M	$55M	$77M	$31M	$-12M	$43M	$126M	$26M
2021	$84M	$14M	$70M	$5M	$-75M	$80M	$83M	$8M
2020	$55M	$144M	$-89M	$0M	$-54M	$54M	$54M	$2M
2019	$5M	$42M	$-37M	$0M	$-3M	$3M	$4M	$1M

Liquidity & Solvency

3/9

Piotroski F-Score

Weak

13.2

Altman Z-Score

Safe

The current ratio of 13.64 indicates an extremely strong liquidity position, meaning Vera Therapeutics can comfortably meet short-term obligations with over $13 in current assets for every $1 of current liabilities.
A debt-to-equity ratio of 0.13 reflects a conservative capital structure, suggesting that only 13% of the company's financing comes from debt and equity holders are not heavily leveraged.
Interest coverage at -41.89x is anomalous; while the metric is negative due to operating losses, the magnitude indicates no near‑term pressure on cash flow to service debt because interest expense is minimal relative to earnings before interest.
Operating cash flow covering 80% of net income (OCF/NI = 0.80) shows that a substantial portion of reported earnings is backed by actual cash generation, reducing reliance on accruals.

Balance Sheet & Cash Flow Health

Vera Therapeutics, Inc. (VERA) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks
2025	$-241M	$194M	$309M	$-1M	$-242M
2024	$-135M	$-425M	$607M	$-1M	$-136M	$-0M
2023	$-92M	$-39M	$134M	$-0M	$-92M
2022	$-68M	$-71M	$102M	$-0M	$-68M
2021	$-24M	$-4M	$54M		$-24M
2020	$-35M	$-0M	$85M	$-0M	$-35M
2019	$-10M	$-0M	$-0M	$-0M	$-10M

Cash Flow Trends

A Piotroski F‑Score of 3/9 suggests modest underlying financial strength, indicating only three out of nine profitability, leverage, and operational criteria are met, which may limit confidence in sustained earnings growth.
The Altman Z‑score of 13.22 places Vera well within the 'safe' zone, implying a very low probability of bankruptcy and reinforcing the resilience implied by its strong liquidity metrics.
An OCF/NI ratio near 0.8 demonstrates that most net income is converted into cash, underscoring high earnings quality despite the modest Piotroski score.

Balance Sheet & Cash Flow Health

Vera Therapeutics, Inc. (VERA) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski F‑Score of 3/9 suggests modest underlying financial strength, indicating only three out of nine profitability, leverage, and operational criteria are met, which may limit confidence in sustained earnings growth.
The Altman Z‑score of 13.22 places Vera well within the 'safe' zone, implying a very low probability of bankruptcy and reinforcing the resilience implied by its strong liquidity metrics.
An OCF/NI ratio near 0.8 demonstrates that most net income is converted into cash, underscoring high earnings quality despite the modest Piotroski score.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▲ +0.9%

vs S&P -22.8pp

ROIC

-46.6%

▲ 3Y ago: -86.3%

Piotroski

3/9

Weak

Vera Therapeutics has delivered a modest 1‑year total return of just 0.9%, trailing the S&P 500 by roughly 23% and generating a negative Sharpe ratio (-0.055), reflecting poor risk‑adjusted performance despite a relatively low beta (0.95). The company’s balance sheet is liquid, with an exceptionally high current ratio of 13.6 and minimal leverage (D/E 0.13), but profitability metrics are deeply negative—ROE -49.6% and ROIC -46.6%—driven by a loss per share of $4.66 and zero revenue to date. Operating cash flow covers about 80% of net income (OCF/NI 0.80), indicating that cash generation is still tied to accounting losses rather than sustainable earnings. The Altman Z‑score of 13.2 signals low bankruptcy risk, yet the negative interest coverage (-41.9x) underscores a fragile capacity to service debt if financing needs arise. Overall, Vera’s strong liquidity contrasts sharply with its unprofitable operations and weak market performance, suggesting that any upside hinges on successful product commercialization rather than current financial fundamentals.

✅ Strengths

A current ratio of 13.6 provides ample short‑term liquidity, allowing the firm to fund R&D milestones without needing immediate external financing.
The low debt‑to‑equity ratio of 0.13 and a Piotroski score of 3 suggest disciplined capital structure management, which reduces dilution risk for shareholders.
An Altman Z‑score of 13.2 places Vera well above the distress threshold, indicating that insolvency is unlikely even if operating losses persist.

⚠️ Risks

Zero revenue and a negative EPS of $4.66 highlight that the company has not yet commercialized any product, making its valuation highly speculative.
ROE of -49.6% and ROIC of -46.6% reveal severe inefficiencies in capital deployment, meaning additional funding may be required to achieve profitability.
Negative interest coverage (-41.9x) signals that Vera cannot currently meet interest obligations from earnings, exposing it to covenant breaches if debt levels rise.

VERA

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.